Effect of EPA/DHA supplementation added on DPP4 inhibitors on lipid and glucose metabolism in patients with type 2 diabetes
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000011169
- Lead Sponsor
- Department of Internal Medicine, Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with a history of hypersensitivity to omega-3 fatty acids ethyl 2) Patients who are bleeding (Hemophilia, capillary fragility, gastrointestinal ulcers, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.) 3) Patients with severe ketosis or diabetic coma/pre-coma 4) Patients with severe infection, trauma or perioperative period
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in HbA1c , GA , 1,5-AG, TC , TG, LDL-C, HDL-C and FFA
- Secondary Outcome Measures
Name Time Method change in adiponectin, fasting plasma glucose, albuminuria, CRP, proinsulin, insulin, free fatty acid, fatty acid composition, and vascular endothelium function